RxDoctor Payments Data

Ryan Schulte, MD

Urology · Des Moines, IANPI 1669598942

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 95.7% of the total across 88 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 14.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $698 and has fallen 53.7% since, to $323 in 2025.

$3,376in general payments, 2019–2025

Across 88 payments — averaging $38.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$475
  • Boston Scientific$414
  • Dornier Medtech America, Inc$291
  • Neotract Inc.$288
  • Olympus America Inc.$191
  • Johnson & Johnson$183
  • plus $2K from 23 others

What the payments were for

  • Food & beverage$3,23396%
  • Education$1444%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,376 in reported general payments places this provider in the 60th percentile of 114 urology providers in Iowa.

See all urology providers in Iowa

Medicare billing

Part B allowed, 2024
$249,745
Medicare patients
406
Services billed
3,121

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ErleadaApalutamide18$263,772
OrgovyxRelugolix33$83,760
MyrbetriqMirabegron98$41,260
Tamsulosin Hcl311$2,391
Solifenacin Succinate116$2,361
Oxybutynin Chloride ErOxybutynin Chloride69$1,176
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates13$830
Finasteride98$689
Ciprofloxacin Hcl95$368
Levofloxacin102$209
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim35$179
Cephalexin22$106
Imipramine Hcl15$83
Tramadol Hcl82$73

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonErleada$183$263,77218 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 114 urology providers in Iowa.

Other urology in Des Moines

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →